Cryo-Cell International (CCEL) AI Stock Analysis

• Market Cap: $36.90M
• Dividend Yield: 8.73%
• Average Volume (3M): 10.30K
• Price to Earnings (P/E): 380.0
• Beta (1Y): 0.02
• Revenue Growth: 1.10%
• EPS Growth: 98.13%
• Country: US
• Employees: 82
• Sector: Healthcare
• Sector Strength: 47
• Industry: Medical - Care Facilities
• EPS (TTM): 0.04
• Shares Outstanding: 8,057,150
• 10 Day Avg. Volume: 16,635
• 30 Day Avg. Volume: 10,304
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 1.43
• Enterprise Value/Revenue: 1.65
• Enterprise Value/Gross Profit: 2.17
• Enterprise Value/Ebitda: 14.62
• 1Y Price Target: $8.50
• Price Target Upside: 85.59% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 50 Neutral
• Price Target: $4.50 ▼(-1.75% Downside)

Cryo-Cell International's overall stock score reflects significant financial and operational challenges. The most impactful factor is the financial instability due to negative equity and low profitability. Technical analysis indicates bearish trends, and the valuation is unattractive with a negative P/E ratio. The high dividend yield is a positive but may not be sustainable. The recent corporate event adds further uncertainty.

Positive Factors

Business Model

Cryo-Cell's core business of processing and storing stem cells has high margins and mostly recurring revenue, contributing to its financial attractiveness.

Dividends

The company maintains a high dividend yield of 18.1%, which is attractive to investors seeking regular income.

Financial Performance

Cryo-Cell International reported a beat on revenue and EBITDA, highlighting resilience in financial performance.

Negative Factors

Arbitration and Legal Risks

The ongoing arbitration against Duke University could potentially impact the company's financial position, with management believing damages could exceed $100M.

Growth Concerns

There is a decrease in new business processed by 18%, impacting overall growth.

Litigation Costs

Higher expenses are expected due to litigation costs and Duke royalty expenses being accrued.

Cryo-Cell International Business Overview & Revenue Model

Company Description

Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, and auto-immune diseases. The company also manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It stores approximately 500,000 cord blood and cord tissue stem cells worldwide. The company markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.

How the Company Makes Money

Cryo-Cell International generates revenue primarily through its cord blood and tissue banking services. The company charges families an initial fee for the collection and processing of stem cells, followed by annual storage fees for maintaining the samples in their facilities. Additional revenue streams include partnerships with healthcare providers, research institutions, and participation in clinical trials, which may involve collaboration in the development of new treatments leveraging stem cells. Furthermore, Cryo-Cell's public cord blood bank contributes to its reputation and outreach, potentially attracting more private clients. The company's growth and earnings are also bolstered by strategic partnerships and advancements in regenerative medicine, which enhance the perceived value of stem cell storage among consumers.

Cryo-Cell International Financial Statement Overview

Summary

Cryo-Cell International's financial performance shows a stable revenue base but significant profitability and balance sheet challenges. The income statement indicates high operational costs impacting net profit. The balance sheet is under pressure with negative equity, highlighting financial instability. However, the cash flow statement provides a silver lining with strong cash generation capabilities, suggesting potential for operational turnaround with improved cost management and strategic financial restructuring.

Income Statement

The income statement shows stable revenue with slight growth over the years, but profitability margins are concerning. The TTM gross profit margin is robust at 76.2%, yet the net profit margin is very low at 0.8%, indicating high operational costs. EBIT and EBITDA margins are 11.9% and 6.9% respectively, which show operational challenges. Revenue growth is modest, but profitability issues suggest room for efficiency improvements.

Balance Sheet

The balance sheet reveals significant financial risks with negative stockholders' equity of -$15.56 million, highlighting insolvency concerns. The debt-to-equity ratio cannot be calculated due to negative equity, indicating a leveraged position. Total assets are declining, and the equity ratio is negative, emphasizing financial instability. Overall, the balance sheet suggests urgent need for capital restructuring.

Cash Flow

Cash flow analysis shows strong operating cash flow relative to net income, with a TTM operating cash flow of $6.26 million and a free cash flow of $5.67 million. The free cash flow growth is positive, reflecting effective cash management despite low net income. The company has managed to maintain positive free cash flow, providing some financial flexibility amidst profitability challenges.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	31.99M	31.34M	30.34M	28.88M	31.15M
Gross Profit	24.04M	22.90M	21.54M	19.90M	21.49M
EBITDA	1.42M	-10.42M	6.65M	5.32M	7.22M
Net Income	402.10K	-9.52M	2.77M	2.08M	3.62M
Balance Sheet
Total Assets	64.68M	61.22M	64.89M	60.66M	46.20M
Cash, Cash Equivalents and Short-Term Investments	3.50M	980.25K	1.72M	8.34M	10.45M
Total Debt	12.93M	10.90M	11.61M	2.82M	6.24M
Total Liabilities	77.89M	72.25M	66.41M	56.48M	48.87M
Stockholders Equity	-13.22M	-11.03M	-1.52M	4.18M	-2.67M
Cash Flow
Free Cash Flow	3.61M	1.28M	-8.60M	974.92K	8.02M
Operating Cash Flow	6.01M	8.92M	8.57M	7.93M	8.47M
Investing Cash Flow	-4.88M	-8.14M	-15.28M	-6.95M	357.49K
Financing Cash Flow	-979.12K	-2.07M	147.86K	-3.07M	-5.00M

Cryo-Cell International Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.58
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CCEL, the sentiment is Negative. The current price of 4.58 is below the 20-day moving average (MA) of 4.75, below the 50-day MA of 4.90, and below the 200-day MA of 6.15, indicating a bearish trend. The MACD of -0.13 indicates Positive momentum. The RSI at 46.73 is Neutral, neither overbought nor oversold. The STOCH value of 61.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CCEL.

Cryo-Cell International Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DCGO	57 Neutral	$168.23M	12.68	-5.98%	―	-41.31%	-163.08%
AMS	52 Neutral	$15.88M	11.72	-9.49%	―	26.61%	-156.30%
Sector *	51 Neutral	$7.88B	-0.12	-39.83%	2.18%	21.38%	-1.56%
CCEL	50 Neutral	$36.90M	380.00	93.38%	8.73%	1.10%	98.13%
PIII	46 Neutral	$52.54M	―	-138.17%	―	4.20%	-54.16%
CCM	40 Neutral	$23.75M	―	14.03%	―	-29.82%	-2.57%
MODV	39 Underperform	$15.36M	―	-951.52%	―	-0.70%	-2.38%

Cryo-Cell International Corporate Events

Cryo-Cell Faces License Termination by Duke University

Cryo-Cell International, Inc. has received a notice of termination from Duke University regarding their Patent and Technology License Agreement, effective May 17, 2025. The termination is based on Duke’s claim that Cryo-Cell breached the agreement, following Cryo-Cell’s arbitration demand alleging fraudulent inducement and multiple breaches by Duke.